KR20100099191A - 수술전 처리 - Google Patents

수술전 처리 Download PDF

Info

Publication number
KR20100099191A
KR20100099191A KR1020107013558A KR20107013558A KR20100099191A KR 20100099191 A KR20100099191 A KR 20100099191A KR 1020107013558 A KR1020107013558 A KR 1020107013558A KR 20107013558 A KR20107013558 A KR 20107013558A KR 20100099191 A KR20100099191 A KR 20100099191A
Authority
KR
South Korea
Prior art keywords
surgery
pharmaceutical composition
brimonidine
pharmaceutically acceptable
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107013558A
Other languages
English (en)
Korean (ko)
Inventor
잭 에이. 데조빈
Original Assignee
갈더마 라보라토리즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 갈더마 라보라토리즈 인코포레이티드 filed Critical 갈더마 라보라토리즈 인코포레이티드
Publication of KR20100099191A publication Critical patent/KR20100099191A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
KR1020107013558A 2007-12-21 2008-12-17 수술전 처리 Ceased KR20100099191A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1591207P 2007-12-21 2007-12-21
US61/015,912 2007-12-21

Publications (1)

Publication Number Publication Date
KR20100099191A true KR20100099191A (ko) 2010-09-10

Family

ID=40801507

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107013558A Ceased KR20100099191A (ko) 2007-12-21 2008-12-17 수술전 처리

Country Status (10)

Country Link
US (1) US20110224215A1 (cg-RX-API-DMAC10.html)
EP (1) EP2230910A4 (cg-RX-API-DMAC10.html)
JP (1) JP5580210B2 (cg-RX-API-DMAC10.html)
KR (1) KR20100099191A (cg-RX-API-DMAC10.html)
CN (1) CN101902913B (cg-RX-API-DMAC10.html)
AU (1) AU2008341112B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0822095A2 (cg-RX-API-DMAC10.html)
CA (1) CA2709199A1 (cg-RX-API-DMAC10.html)
NZ (1) NZ586302A (cg-RX-API-DMAC10.html)
WO (1) WO2009082452A1 (cg-RX-API-DMAC10.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
PT2818184T (pt) * 2007-11-16 2019-01-28 Aclaris Therapeutics Inc Composições e métodos para o tratamento de púrpura
US20120295914A1 (en) * 2009-05-29 2012-11-22 Galderma Research & Development Combination of adrenergic receptor agonist alpha-1 or alpha-2, preferably brimonidine with fillers, preferably hyaluronic acid
WO2011117378A2 (en) * 2010-03-26 2011-09-29 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
CN103298472A (zh) 2010-03-26 2013-09-11 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
ES2498217T5 (es) * 2010-10-21 2018-03-19 Galderma S.A. Composición en forma de gel basada en brimonidina
RU2013123043A (ru) * 2010-10-21 2014-12-10 Галдерма С.А. Гелевая композиция для местного применения
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
WO2013057579A2 (en) 2011-10-19 2013-04-25 Galderma Pharma S.A. Method of reducing facial flushing associated with systemic use of phosphodiesterase type 5 inhibitors
JP6339364B2 (ja) * 2013-12-27 2018-06-06 カズマパートナーズ株式会社 無定形ブリモニジン酒石酸塩及びその製造方法
WO2019083771A1 (en) * 2017-10-23 2019-05-02 Microcures, Inc. METHOD FOR IMPROVING THE RECOVERY OF A SKIN TREATED WITH A COSMETIC LASER

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2154979A1 (en) * 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7439241B2 (en) 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
PT2818184T (pt) * 2007-11-16 2019-01-28 Aclaris Therapeutics Inc Composições e métodos para o tratamento de púrpura

Also Published As

Publication number Publication date
US20110224215A1 (en) 2011-09-15
WO2009082452A1 (en) 2009-07-02
CN101902913B (zh) 2014-06-18
JP5580210B2 (ja) 2014-08-27
AU2008341112B2 (en) 2014-02-06
EP2230910A1 (en) 2010-09-29
EP2230910A4 (en) 2011-04-13
NZ586302A (en) 2013-03-28
CA2709199A1 (en) 2009-07-02
AU2008341112A1 (en) 2009-07-02
BRPI0822095A2 (pt) 2014-10-07
CN101902913A (zh) 2010-12-01
JP2011507845A (ja) 2011-03-10

Similar Documents

Publication Publication Date Title
JP5580210B2 (ja) 手術前治療
JP5670196B2 (ja) 紫斑を治療する組成物および方法
EP2200617A1 (en) Improved brimonidine compositions for treating erythema
JP2016525553A (ja) 皮膚肥厚の治療法
AU2012324544B2 (en) Method for treating capillary hemangiomas
EP2994120B1 (en) Alpha adrenergic agonists for the treatment of tissue trauma
EP3049088B1 (en) Prostaglandin f2alpha and analogues thereof for treating atrophic cutaneous scarring
KR20140091543A (ko) 전신용인 포스포디에스터레이즈타입-5-억제제에 의한 안면홍조를 경감시키는 방법
HK1222558B (en) Alpha adrenergic agonists for the treatment of tissue trauma

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100618

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131210

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141229

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20150501

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20141229

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I